Hainsworth J D, Greco F A
Sarah Cannon (Minnie Pearl) Cancer Center, Centennial Medical Center, Nashville, TN, USA.
Ann Oncol. 1995 Apr;6(4):325-41. doi: 10.1093/oxfordjournals.annonc.a059180.
Since the beginning of its clinical development 20 years ago, etoposide has become an important and widely used agent in clinical oncology. Its integral role in the treatment of germ cell tumors and small-cell lung cancer seems unlikely to diminish in the future, and its use in non-Hodgkin's lymphoma and in various high dose regimens will probably continue to increase. Active investigation continues regarding the optimal dose and schedule of etoposide, and it is likely that these investigations will result in further improvement of its clinical activity in patients with sensitive tumor types. Continued clinical investigation may result in the identification of active etoposide containing combination regimens for ovarian cancer, breast cancer, and some of the childhood malignancies. Exciting possibilities for the future include exploration of etoposide in combination with the topoisomerase I inhibitors, as well as the development of drugs to reverse drug resistance. During the next 10 years, the applications and importance of this unique drug will continue to increase.
自20年前开始临床研发以来，依托泊苷已成为临床肿瘤学中一种重要且广泛使用的药物。它在生殖细胞肿瘤和小细胞肺癌治疗中的不可或缺作用在未来似乎不太可能减弱，其在非霍奇金淋巴瘤及各种高剂量方案中的应用可能还会继续增加。关于依托泊苷的最佳剂量和给药方案的积极研究仍在继续，这些研究很可能会进一步提高其在敏感肿瘤类型患者中的临床活性。持续的临床研究可能会确定含依托泊苷的有效联合方案用于治疗卵巢癌、乳腺癌以及一些儿童恶性肿瘤。未来令人兴奋的可能性包括探索依托泊苷与拓扑异构酶I抑制剂联合使用，以及开发逆转耐药性的药物。在未来10年里，这种独特药物的应用和重要性将持续增加。
